Cargando…

Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream

Named after the two-faced Roman god of doorways, Janus kinases (JAKs) represent a class of tyrosine kinases. The JAK signaling pathway is pivotal for the downstream signaling of inflammatory cytokines, including interleukins, interferons, and multiple growth factors. This article provides an overvie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, Paul, Yao, Wenqing, Shepard, Stacey, Covington, Maryanne, Lee, Jim, Lofland, Jennifer, Naim, Ahmad, Sheth, Trupti, Parikh, Bhavnish, Yeleswaram, Swamy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8309120/ https://www.ncbi.nlm.nih.gov/pubmed/34371735 http://dx.doi.org/10.3390/pharmaceutics13071044

Ejemplares similares

Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment
por: Yeleswaram, Swamy, et al.
Publicado: (2020)

Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies
por: Gong, Xiaohua, et al.
Publicado: (2021)

A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis
por: Bissonnette, Robert, et al.
Publicado: (2022)

Design of Clinical Trials Evaluating Ruxolitinib, a JAK1/JAK2 Inhibitor, for Treatment of COVID-19–Associated Cytokine Storm
por: Langmuir, Peter, et al.
Publicado: (2020)

Ruxolitinib cream for the treatment of cutaneous sarcoidosis
por: Smith, Jeffrey S., et al.
Publicado: (2023)

Treatment of cutaneous lupus with topical ruxolitinib cream
por: Park, Jonathan J., et al.
Publicado: (2022)

Sustained‐release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis
por: Verstovsek, Srdan, et al.
Publicado: (2018)

Improvement of necrobiosis lipoidica with topical ruxolitinib cream after prior nonresponse to compounded topical tofacitinib cream
por: Nugent, Shannon, et al.
Publicado: (2022)

Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis
por: Scuron, Monika D., et al.
Publicado: (2021)

Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III Studies
por: Bloudek, Lisa, et al.
Publicado: (2022)

Atomic Simulation of the Binding of JAK1 and JAK2 with the Selective Inhibitor Ruxolitinib
por: Kondratyev, Maxim, et al.
Publicado: (2022)

Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis
por: Keenan, Camille, et al.
Publicado: (2021)

Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Recalcitrant Hailey-Hailey disease successfully treated with topical ruxolitinib cream and dupilumab
por: Khang, Juna, et al.
Publicado: (2023)

The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases
por: TÜRK, Can, et al.
Publicado: (2019)

Correction to: Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2023)

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
por: Mascarenhas, J, et al.
Publicado: (2012)

The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19
por: Goker Bagca, Bakiye, et al.
Publicado: (2020)

The JAK1/2 inhibitor ruxolitinib delays premature aging phenotypes
por: Griveau, Audrey, et al.
Publicado: (2020)

New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib
por: Marcuzzi, Annalisa, et al.
Publicado: (2022)

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study
por: Vannucchi, Alessandro Maria, et al.
Publicado: (2017)

Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib
por: Shide, K, et al.
Publicado: (2017)

The JAK inhibitor ruxolitinib abrogates immune hepatitis instigated by concanavalin A in mice
por: Shaker, Mohamed E., et al.
Publicado: (2022)

A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma
por: Van Den Neste, Eric, et al.
Publicado: (2018)

P1428: IMPLICATIONS OF THE RUXOLITINIB (JAK1/JAK2 INHIBITOR) ON GRAFT-VERSUS-LEUKAEMIA EFFECT MEDIATED BY THE NK CELL.
por: Durán, C., et al.
Publicado: (2022)

Baseline Levels of Circulating Inflammatory Biomarkers Stratify Patients with Vitiligo Who Significantly Repigment after Treatment with Ruxolitinib Cream
por: Howell, Michael D., et al.
Publicado: (2023)

The JAK inhibitor ruxolitinib reduces inflammation in an ILC3-independent model of innate immune colitis
por: Overstreet, A.M., et al.
Publicado: (2018)

Ruxolitinib, a JAK1/2 Inhibitor as Treatment for Paraneoplastic Pemphigus: A Case Report
por: FAN, Birao, et al.
Publicado: (2022)

Evaluation of drug–drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling
por: Ji, Tao, et al.
Publicado: (2022)

Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2(V617F) cells
por: Machado-Neto, João Agostinho, et al.
Publicado: (2015)

Case Report: The JAK-Inhibitor Ruxolitinib Use in Aicardi-Goutieres Syndrome Due to ADAR1 Mutation
por: Cattalini, Marco, et al.
Publicado: (2021)

Combined Ruxolitinib and Venetoclax Treatment in a Patient with a BCR-JAK2 Rearranged Myeloid Neoplasm
por: Lap, Coen J., et al.
Publicado: (2021)

Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome
por: Huarte, Eduardo, et al.
Publicado: (2021)

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
por: Verstovsek, Srdan, et al.
Publicado: (2014)

Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene
por: Helbig, Grzegorz, et al.
Publicado: (2017)

Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study
por: Vannucchi, Alessandro M., et al.
Publicado: (2020)

Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures
por: Singer, Jack W., et al.
Publicado: (2019)

The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial
por: Hammersen, J., et al.
Publicado: (2023)

Ruxolitinib for myelofibrosis
por: GU, LIAN, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ujoseovac33acdli2dlnj5skfg